As Don alluded to, the FDA has until the end of November (60 days from the completion of the application) to award, or not award, expedited review to Pona.
That would seem to be the next likely catalyst. No reason that they need to take the entire 60 days though. They could announce it sooner. This week would be nice.
Oppenheimer has a new analyst. The previous guy Brett Holley was a big Aria bull. I knew an Oppenheimer broker and he spoke often of how Holley was bullish on Aria. I don't think the new guy follows the ariad story or is quite as bullish on aria.
News 
Market Data 
Discover 
